Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 Nov;38(6):399–405. doi: 10.1007/BF01517210

Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients

Xiu Qing Huang 1, Malcolm S Mitchell 2, Peter E Liggett 3, A Linn Murphree 3, June Kan-Mitchell 1,✉
PMCID: PMC11038977  PMID: 8205561

Abstract

To characterize the anti-melanoma reactivity of CD8+ cytotoxic T lymphocytes (CTL) from choroidal melanoma patients, CTL clones were isolated from the peripheral blood of three patients after mixed lymphocyte/tumor cell culture (MLTC). Clones were derived from lymphocytes stimulated by allogeneic (OCM-1, A24, A28) or autologous (OCM-3, Al, A30) melanoma cells. Their reactivity against a panel of HLA-typed melanoma and nonmelanoma cells was assessed, to determine whether a single CTL clone could recognize and lyse a variety of allogeneic melanoma cell lines. While proportionately more clones derived from autologous MLTC were melanoma-specific than allogeneic MLTC (42% versus 14%), melanoma-specific CTL were recovered from both. Notably, a novel melanoma specificity was identified. These CTL clones were termed non-fastidious because they were capable of lysing melanoma cells with which they had no HLA class I alleles in common. Nonetheless, lysis was mediated by the HLA class I molecule. Since lysis was specific for melanoma cells, these CTL appeared to recognize a shared melanoma peptide(s). Because of their prevalence, we propose that non-fastidious CTL are integral to human anti-melanoma T cell immunity. This reinforces clinical findings that allogeneic melanomas can substitute for autologous tumors in active specific immunotherapy. By circumventing the need for autologous melanoma, it is possible to treat patients after removal of the primary choroidal melanoma in an attempt to prevent metastasis.

Key words: Cytotoxic T cell, Clone, Choroidal melanoma, Melanoma-specific, HLA restriction

Footnotes

Supported by USPHS grants EY-09031 and EY-09427, and the Lucy Adams Choroidal Melanoma Research Fund to J. K.-M.

References

  • 1.Hersey P. Examination of the scientific basis for vaccines in treatment of melanoma. Vaccine Res. 1992;1:357. [Google Scholar]
  • 2.Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: phase 1 trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988;48:5883. [PubMed] [Google Scholar]
  • 3.Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WB, Dean G, Stevenson L. Active-specific immunotherapy for melanoma. J Clin Oncol. 1990;8:856. doi: 10.1200/JCO.1990.8.5.856. [DOI] [PubMed] [Google Scholar]
  • 4.Mitchell MS. Attempts to optimize active specific immunotherapy for melanoma. Int Rev Immunol. 1991;7:331. doi: 10.3109/08830189109114878. [DOI] [PubMed] [Google Scholar]
  • 5.Topalian SL, Rosenberg SA. Tumor infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans. In: De DeVita VT, Hellman SA, Rosenberg SA, editors. Important advances in oncology. Philadelphia: Lippincott; 1990. p. 19. [PubMed] [Google Scholar]
  • 6.Vose BM, Vanky F, Klein E. Lymphocyte cytotoxicity against autologous tumor biosy cells in humans. Int J Cancer. 1977;20:512. doi: 10.1002/ijc.2910200407. [DOI] [PubMed] [Google Scholar]
  • 7.Mukherji B, Flowers L, Rothman L, Nathanson L. Spontaneous in vitro cytotoxicity against autochthonous human melanoma cells. J Immunol. 1980;124:412. [PubMed] [Google Scholar]
  • 8.Itoh K, Tilden AB, Balch CM. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic metanomas. Cancer Res. 1986;46:3011. [PubMed] [Google Scholar]
  • 9.Parmiani G, Anichini A, Fossati G. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst. 1990;82:361. doi: 10.1093/jnci/82.5.361. [DOI] [PubMed] [Google Scholar]
  • 10.Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239. doi: 10.1016/0039-6257(88)90173-7. [DOI] [PubMed] [Google Scholar]
  • 11.Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992;110:245. doi: 10.1001/archopht.1992.01080140101036. [DOI] [PubMed] [Google Scholar]
  • 12.Shields JA, Augsburger JJ, Donoso LA, Bernardino VB., Jr Hepatic metastasis and orbita recurrence of uveal melanoma after 42 years. Am J Ophthalmol. 1985;100:666. doi: 10.1016/0002-9394(85)90621-x. [DOI] [PubMed] [Google Scholar]
  • 13.Albert DM, Niffenegger AS, Wilson JKV. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol. 1992;36:429. doi: 10.1016/s0039-6257(05)80024-4. [DOI] [PubMed] [Google Scholar]
  • 14.de la Cruz PO, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112. doi: 10.1002/1097-0142(19900101)65:1<112::aid-cncr2820650123>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 15.Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci. 1990;31:2106. [PubMed] [Google Scholar]
  • 16.Ksander BR, Rubsamen PE, Olsen KR, Cousins SW, Streilein JW. Studies of tumor-infiltration lymphocytes from a human choroidal melanoma. Invest Ophthalmol Vis Sci. 1991;32:3198. [PubMed] [Google Scholar]
  • 17.Niederkorn JY. Immune privilege and immune regulation in the eye. Adv Immunol. 1990;48:191. doi: 10.1016/s0065-2776(08)60755-5. [DOI] [PubMed] [Google Scholar]
  • 18.Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci. 1989;30:829. [PubMed] [Google Scholar]
  • 19.Kan-Mitchell J, Liggett PE, Harel W, Steinman L, Nitta T, Oksenberg JR, Posner MR, Mitchell MS. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunol Immunother. 1991;33:333. doi: 10.1007/BF01756599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Uchida A. Biological significance of autologous tumourkilling activity and its induction therapy. Cancer Immunol Immunother. 1993;37:75. doi: 10.1007/BF01517038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Knapp W, Rieber P, Dorken B, Schmidt RE, Stein H, Borne AEGKrvd. Towards a better definition of human leucocyte surface molecules. Immunol Today. 1989;10:253. doi: 10.1016/0167-5699(89)90135-7. [DOI] [PubMed] [Google Scholar]
  • 22.Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cells restriction-specificity, function and responsiveness. Adv Immunol. 1979;27:51. doi: 10.1016/s0065-2776(08)60262-x. [DOI] [PubMed] [Google Scholar]
  • 23.Mukherji B, Chakraborty NG, Sivanandham M. T cell clones that react against autologous human tumors. Immunol Rev. 1990;116:33. doi: 10.1111/j.1600-065x.1990.tb00803.x. [DOI] [PubMed] [Google Scholar]
  • 24.Darrow TL, Slingluff CL, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. J Immunol. 1989;142:3329. [PubMed] [Google Scholar]
  • 25.Woelfel T, Klehmann E, Muller C, Schutt K, Zum Bushenfelde KHM, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med. 1989;170:797. doi: 10.1084/jem.170.3.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol. 1991;146:1692. [PubMed] [Google Scholar]
  • 27.Kan-Mitchell J, Huang X-Q, Steinman L, Oksenberg JR, Harel W, Parker JW, Goedegebuure PS, Darrow TL, Mitchell MS. Clonal analysis of in vivo-activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother. 1993;37:15. doi: 10.1007/BF01516937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Schwartz BD. The human major histocompatibility human leukocyte antigen (HLA) complex. In: Stites DP, Terr AI, editors. Basic and clinical immunology. 7th edn. Norwalk, Conn: Appleton & Lange; 1991. p. 45. [Google Scholar]
  • 29.Lopez de Castro JA, Strominger JL, Strong DM, Orr HT. Structure of crossreactive human histocompatibility antigens HLA-A28 and HLA-A2: possible implications for the generation of HLA polymorphism. Proc Natl Acad Sci USA. 1982;79:3813. doi: 10.1073/pnas.79.12.3813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Pandovan E, Casorati G, Dellabona P, Meyer S, Brockhaus M, Lanzavecchia A. Expression of two T cell receptor α chains: dual receptor T cells. Science. 1993;262:422. doi: 10.1126/science.8211163. [DOI] [PubMed] [Google Scholar]
  • 31.Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987;329:506. doi: 10.1038/329506a0. [DOI] [PubMed] [Google Scholar]
  • 32.Chien Y-H, Davis MM. How αβ T-cell receptors “see” peptide/MHC complexes. Immunol Today. 1993;14:597. doi: 10.1016/0167-5699(93)90199-u. [DOI] [PubMed] [Google Scholar]
  • 33.Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today. 1993;14:602. doi: 10.1016/0167-5699(93)90200-5. [DOI] [PubMed] [Google Scholar]
  • 34.Anichini A, Mortarini R, Alberti S, Mantovani A, Parmiani G. T-cell-receptor engagement and tumor ICAM-I up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis. Int J Cancer. 1993;53:994. doi: 10.1002/ijc.2910530623. [DOI] [PubMed] [Google Scholar]
  • 35.Becker JC, Terineer C, Schmidt RE, Brocker E-B. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol. 1993;151:7224. [PubMed] [Google Scholar]
  • 36.Goedegebuure PS, Harel W, LeMay L, Kan-Mitchell J, Mitchell MS. Cytotoxic CD4+ lymphocytes clones reactive with melanoma: The role of HLA and accessory molecules. Vaccine Res. 1993;2:249. [Google Scholar]
  • 37.Davis MM, Chien Y-H. Topology and affinity of T-cell receptor mediated recognition of peptide-MHC complexes. Curr Opin Immunol. 1993;5:45. doi: 10.1016/0952-7915(93)90079-8. [DOI] [PubMed] [Google Scholar]
  • 38.Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol. 1993;11:385. doi: 10.1146/annurev.iy.11.040193.002125. [DOI] [PubMed] [Google Scholar]
  • 39.Parmiani G. Tumor immunity as autoimmunity, tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today. 1993;14:536. doi: 10.1016/0167-5699(93)90183-L. [DOI] [PubMed] [Google Scholar]
  • 40.Mueller BM, Reisfeld RA. Potential of the scid mouse as a host for human tumors. Cancer Metastasis Rev. 1991;10:193. doi: 10.1007/BF00050791. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES